BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy to treat advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. This approval expands Tevimbraās indication in the US, where it was previously approved for treating unresectable or metastatic oesophageal squamous cell carcinoma (ESCC …
